CTRI/2023/02/049667尚未招募2 期
A phase II randomised, open label study to determine the efficacy of granulocyte transfusion amongst paediatric cancer patients with carbapenem-resistant gram-negative sepsis
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •I. Children 1-18 years of age
- •II. Subjects diagnosed and treated with hematolymphoid neoplasm.
- •III. ANC <500/mm3 with expected recovery period of >5 days
- •IV. Carbepenem resistant gram-negative sepsis
排除标准
- •I. Any subject requiring more than fluid boluses (20ml/kg) to correct hypotension
- •II. Any subject admitted in intensive care unit
- •III. Any subject with ejection fraction <20%
- •IV. Any subject with necrotizing enterocolitis
- •V. Any subject diagnosed with solid tumor
- •VI. Subjects previously enrolled in this study
研究者
相似试验
进行中（未招募）
1 期
Investigating AKT inhibitors in combination with immunotherapy and chemotherapy in patients with triple negative breast cancerTriple negative breast cancerMedDRA version: 21.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000977-62-DEQueen Mary University London142
进行中（未招募）
不适用
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Best Supportive Care Alone In Patients Affected By Recurrent Liver Cancer.EUCTR2013-001426-26-ESPfizer Inc, 235 East 42nd Street, New York, NY 10017180
进行中（未招募）
不适用
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Best Supportive Care Alone In Patients Affected By Recurrent Liver Cancer.EUCTR2013-001426-26-ITPfizer Inc, 235 East 42nd Street, New York, NY 10017180
进行中（未招募）
2 期
A study to evaluate preventive treatments for talquetamab-related oral toxicityMultiple myelomaCancerISRCTN72589181Janssen-Cilag International NV120
进行中（未招募）
1 期
M6620 in Combination with Avelumab and Carboplatin versus standard chemotherapy in Subjects with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10038977Term: Retroperitoneal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001534-17-GBMerck KGaA90